Pyelonephritis

Nabriva and Vizient Enter into Agreement to Make XENLETA® (lefamulin) Available to Vizient’s Pharmacy Network Program

Retrieved on: 
Thursday, September 9, 2021

Nabriva CEO Ted Schroeder commented, We are excited by Vizients decision to enter into an agreement to make XENLETA available to their Hospital Pharmacy Network, enabling access across Vizient member hospitals, which make up more than half of U.S. hospitals.

Key Points: 
  • Nabriva CEO Ted Schroeder commented, We are excited by Vizients decision to enter into an agreement to make XENLETA available to their Hospital Pharmacy Network, enabling access across Vizient member hospitals, which make up more than half of U.S. hospitals.
  • Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections.
  • Nabriva Therapeutics received U.S. Food and Drug Administration approval for XENLETA (lefamulin injection, lefamulin tablets), the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP).
  • These forward-looking statements should not be relied upon as representing Nabriva Therapeutics views as of any date subsequent to the date of this press release.

Lefamulin Receives Approval in Taiwan for Treatment of Community-Acquired Pneumonia

Retrieved on: 
Wednesday, September 8, 2021

The anticipated launch timing of XENLETA in Taiwan is undecided.

Key Points: 
  • The anticipated launch timing of XENLETA in Taiwan is undecided.
  • Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections.
  • Nabriva Therapeutics received U.S. Food and Drug Administration approval for XENLETA (lefamulin injection, lefamulin tablets), the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP).
  • These forward-looking statements should not be relied upon as representing Nabriva Therapeutics views as of any date subsequent to the date of this press release.

Spero Therapeutics to Present at Three Upcoming Investor Conferences

Retrieved on: 
Tuesday, September 7, 2021

Webcasts of the presentations may also be accessed through Spero Therapeutics website ( www.sperotherapeutics.com ) on the Events and Presentations page under the Investors and Media tab.

Key Points: 
  • Webcasts of the presentations may also be accessed through Spero Therapeutics website ( www.sperotherapeutics.com ) on the Events and Presentations page under the Investors and Media tab.
  • Replays of the presentations will be available on the website following the conclusion of the respective events.
  • Spero Therapeutics, Inc.is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug-resistant (MDR) bacterial infections and rare diseases.
  • InSeptember 2020, Spero announced positive top-line results from its Phase 3 ADAPT-PO clinical trial of tebipenem HBr in cUTI and AP.

Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Wednesday, September 1, 2021
Company, Employment, GLOBE, Fosfomycin, Infection, Merck, United, Nasdaq, Urinary tract infection, Food, Bronchopneumonia, Therapy, Pyelonephritis, Tablet, NASDAQ, Calcinosis cutis, Pharmaceutical industry

These grants wereawarded pursuant to the Nasdaq inducement grant exception as a component of new hire employment compensation.

Key Points: 
  • These grants wereawarded pursuant to the Nasdaq inducement grant exception as a component of new hire employment compensation.
  • The stock option awards were approved by Nabriva Therapeutics Compensation Committee and were granted as an inducement material to each employees acceptance of employment in accordance with Nasdaq Listing Rule 5635(c)(4).
  • Each of the stock options is subject to the terms and conditions of a stock option agreement covering the grant and Nabriva Therapeutics 2021 Inducement Share Incentive Plan.
  • Nabriva Therapeuticsis a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections.Nabriva TherapeuticsreceivedU.S.

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Tuesday, August 31, 2021
Employment, Financial compensation, GLOBE, Infection, MDR, Nasdaq, Urinary tract infection, NTM, Therapy, AP, Pyelonephritis, Tebipenem, Drug of last resort, HBR, Calcinosis cutis, Degenerative disease, Pharmaceutical industry

The stock options were granted as inducements material to the new employees becoming employees of Spero in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The stock options were granted as inducements material to the new employees becoming employees of Spero in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Spero (or following a bona fide period of non-employment), as an inducement material to such individuals entering into employment with Spero, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.
  • Spero Therapeutics, Inc.is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug-resistant (MDR) bacterial infections and rare diseases.
  • InSeptember 2020, Spero announced positive top-line results from its Phase 3 ADAPT-PO clinical trial of tebipenem HBr in cUTI and AP.

Nabriva Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Retrieved on: 
Tuesday, August 31, 2021
Company, Webcast, GLOBE, Fosfomycin, Infection, Merck, Urinary tract infection, Food, Bronchopneumonia, Therapy, Pyelonephritis, Tablet, NASDAQ, Food and Drug Administration, Conference, Tuberculosis verrucosa cutis, Pharmaceutical industry

The presentation may be accessed by visiting the "Investors" section of the Company's website under the "Events and Presentations" tab at www.nabriva.com .

Key Points: 
  • The presentation may be accessed by visiting the "Investors" section of the Company's website under the "Events and Presentations" tab at www.nabriva.com .
  • Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections.
  • Nabriva Therapeutics received U.S. Food and Drug Administration approval for XENLETA (lefamulin injection, lefamulin tablets), the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP).
  • Nabriva Therapeutics is also developing CONTEPO (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTI), including acute pyelonephritis.

The Worldwide Cystoscope Industry is Expected to Reach $791 Million by 2026 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 25, 2021
Medical Devices, Health, Urology, Growth, Cystoscopy, Cancer, National Kidney Foundation, Incidence, Urinary tract infection, Urinary bladder, Infection, Feline lower urinary tract disease, Prostate, Prevalence, Man, Ageing, Bladder cancer, Time-invariant system, Bleeding, Adult, Solution, National library, Cancer Research UK, Pyelonephritis, Hematuria, Light, Prostate cancer, Woman, Urethra, Medical imaging

The company had announced that it would launch a novel single-use, sterile, and high-resolution cystoscope in the year 2022.

Key Points: 
  • The company had announced that it would launch a novel single-use, sterile, and high-resolution cystoscope in the year 2022.
  • These trends and developments are expected to play a major role in the market growth, during the forecast period.
  • The growth in the global cystoscope market may be attributed to the rising prevalence of urinary tract diseases globally.
  • These trends are expected to accelerate the demand for novel cystoscope devices and applications, in the coming years.

Global Urinary Tract Infections Markets, Epidemiology and Patient Flow Analysis Report 2020-2035 - ResearchAndMarkets.com

Retrieved on: 
Friday, May 14, 2021
Health, General Health, Medical specialties, Clinical medicine, Medicine, Infectious diseases, Epidemiology, Urinary tract infection, Infection, Enterobacteriaceae, Fluoroquinolone antibiotics, Healthcare-associated infections, Urinary incontinence, Pyelonephritis

b'The "Global Urinary Tract Infections Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Urinary Tract Infections Epidemiology and Patient Flow Analysis - 2021, provides Urinary Tract Infections epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Urinary Tract Infections Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Urinary Tract Infections Epidemiology and Patient Flow Analysis - 2021, provides Urinary Tract Infections epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Urinary Tract Infections patients, history of the disease at the population level (Urinary Tract Infections prevalence, Urinary Tract Infections incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nUrinary Tract Infections patient flow: Urinary Tract Infections prevalence, diagnosed, and drug-treated patients\nDemographics: Urinary Tract Infections patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Urinary Tract Infections market sizing, assessing market potential, and developing drug forecast models\nIdentify Urinary Tract Infections patients segments through age groups, gender, and disease sub-types\nEvaluate Urinary Tract Infections market opportunities, identify target patient population\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210514005206/en/\n'

Nabriva Therapeutics to Report First Quarter 2021 Financial Results and Recent Corporate Highlights on May 6, 2021

Retrieved on: 
Thursday, April 29, 2021
Medical specialties, Chemical compounds, Clinical medicine, Antibiotics, Epoxides, Phosphonic acids, Fosfomycin, Urinary tract infection, Pleuromutilin, Pyelonephritis, Forward-looking statement, Lefamulin

Nabriva Therapeutics received U.S. Food and Drug Administration approval for XENLETA\xc2\xae (lefamulin injection, lefamulin tablets), the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP).

Key Points: 
  • Nabriva Therapeutics received U.S. Food and Drug Administration approval for XENLETA\xc2\xae (lefamulin injection, lefamulin tablets), the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP).
  • Nabriva Therapeutics is also developing CONTEPO\xe2\x84\xa2 (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTI), including acute pyelonephritis.
  • In addition, the forward-looking statements included in this press release represent Nabriva Therapeutics\xe2\x80\x99 views as of the date of this press release.
  • These forward-looking statements should not be relied upon as representing Nabriva Therapeutics\xe2\x80\x99 views as of any date subsequent to the date of this press release.\n'

Spero Therapeutics Announces Issuance of Allowance for a U.S. Patent Covering Lead Candidate Tebipenem HBr

Retrieved on: 
Thursday, January 21, 2021
Medical specialties, Medicine, Clinical medicine, Prodrugs, Tebipenem, Carbapenem, Urinary tract infection, Pyelonephritis, Bromine

InSeptember 2020, Spero announced positive top-line results from its Phase 3 ADAPT-PO clinical trial of tebipenem HBr in cUTI and AP.

Key Points: 
  • InSeptember 2020, Spero announced positive top-line results from its Phase 3 ADAPT-PO clinical trial of tebipenem HBr in cUTI and AP.
  • 10,889,587 covers a crystalline form and pharmaceutical compositions of tebipenem HBr, including the methods of manufacturing and methods of use.
  • InSeptember 2020, Spero announced positive top-line results from its Phase 3 ADAPT-PO clinical trial of tebipenem HBr in cUTI and AP.
  • Speros lead product candidate, tebipenem HBr (tebipenem pivoxil hydrobromide; formerly SPR994), is being developed as the first oral carbapenem antibiotic for use in complicated urinary tract infections (cUTI) and acute pyelonephritis (AP).